恩威医药(301331) - 2023 Q1 - 季度财报

Key Financial Data Core Financial Indicators In Q1 2023, the company achieved robust performance with $201 million in operating revenue and $27.67 million in net profit attributable to shareholders, alongside positive operating cash flow and stable financial health | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue ($) | 200,800,387.47 | 157,604,605.75 | 27.41% | | Net Profit Attributable to Shareholders ($) | 27,669,629.76 | 20,258,223.51 | 36.58% | | Net Cash Flow from Operating Activities ($) | 505,655.16 | -4,394,061.58 | 111.51% | | Basic Earnings Per Share ($/share) | 0.3945 | 0.3851 | 2.44% | | Balance Sheet Indicators | End of Current Period | End of Prior Year | Change from Year-End | | Total Assets ($) | 1,431,675,016.45 | 1,406,080,553.60 | 1.82% | | Total Equity Attributable to Shareholders ($) | 1,180,672,946.34 | 1,153,003,316.58 | 2.40% | Non-Recurring Gains and Losses Analysis Total non-recurring gains and losses for the period amounted to $1.876 million, positively impacting current net profit, primarily comprising $1.174 million in government grants and $1.066 million in investment income from transactional financial assets | Item | Amount for Current Period ($) | | :--- | :--- | | Gains and Losses from Disposal of Non-Current Assets | -41,203.90 | | Government Grants | 1,174,435.23 | | Gains and Losses Related to Transactional Financial Assets | 1,065,912.13 | | Other Non-Operating Income and Expenses | 10,073.57 | | Less: Income Tax Impact | 332,789.22 | | Total | 1,876,427.81 | Reasons for Changes in Key Financial Indicators The growth in key profit indicators for the period is primarily attributed to increased operating revenue, while the significant improvement in operating cash flow (up 111.51%) resulted from increased sales collections, indicating enhanced core business cash generation - The increase in net profit attributable to shareholders (up 36.58% year-over-year) and non-recurring net profit (up 30.49% year-over-year) was primarily due to increased operating revenue[8] - Net cash flow from operating activities increased by 111.51% year-over-year, turning positive, primarily due to increased sales collections[9] Shareholder Information Shareholder Ownership Structure As of the end of the reporting period, the company had 10,849 common shareholders, with a concentrated equity structure where the top four shareholders are related parties collectively holding over 65% of shares, and the actual controllers Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong indirectly control 67.23% of the company's equity through concerted action agreements - The total number of common shareholders at the end of the reporting period was 10,849[10] - The company's actual controllers, Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong, indirectly control 67.23% of the company's equity through Enwei Group, Chengdu Jiewei, Chengdu Ruijinheng, Chengdu Zehong, and Changdu Jieweite, forming a concerted action group[10] - The largest shareholder, Chengdu Enwei Investment (Group) Co., Ltd., holds 28.64% of the company's shares, with a portion (4.5 million shares) pledged[10] Other Significant Matters Other Significant Matters During the reporting period, the company had no other significant matters requiring disclosure - The company had no other applicable or significant matters to explain during this reporting period[12] Quarterly Financial Statements Consolidated Balance Sheet As of March 31, 2023, the company's total assets were $1.432 billion, up 1.82% from the beginning of the year with a stable asset structure, while total liabilities slightly decreased to $251 million, and shareholders' equity increased by 2.40% to $1.181 billion, primarily due to accumulated current period profits | Item | End of Period Balance ($) | Beginning of Year Balance ($) | | :--- | :--- | :--- | | Total Assets | 1,431,675,016.45 | 1,406,080,553.60 | | Total Current Assets | 987,194,143.53 | 957,287,374.17 | | Total Non-Current Assets | 444,480,872.92 | 448,793,179.43 | | Total Liabilities | 251,002,070.11 | 253,077,237.02 | | Total Shareholders' Equity | 1,180,672,946.34 | 1,153,003,316.58 | Consolidated Income Statement In Q1 2023, the company achieved total operating revenue of $201 million, a 27.41% year-over-year increase, with operating costs up 24.8%, selling expenses up 36.3%, and R&D expenses significantly increasing by 124.8%, ultimately resulting in a net profit attributable to parent company shareholders of $27.67 million, up 36.58% | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | I. Total Operating Revenue | 200,800,387.47 | 157,604,605.75 | | II. Total Operating Costs | 168,140,196.62 | 134,049,118.32 | | Selling Expenses | 59,019,548.45 | 43,296,237.94 | | Research and Development Expenses | 2,127,675.84 | 946,766.85 | | III. Operating Profit | 34,137,438.81 | 23,128,821.52 | | V. Net Profit | 27,669,629.76 | 20,258,223.51 | Consolidated Cash Flow Statement In Q1 2023, the company's cash flow significantly improved, with net cash flow from operating activities turning positive at $0.506 million from -$4.394 million in the prior year, and net cash flow from investing activities at $22.06 million primarily due to cash received from investment-related activities, increasing the period-end cash and cash equivalents balance to $364.12 million | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 505,655.16 | -4,394,061.58 | | Net Cash Flow from Investing Activities | 22,062,212.40 | -11,212,372.79 | | Net Cash Flow from Financing Activities | 0.00 | -352,000.00 | | Net Increase in Cash and Cash Equivalents | 22,541,970.22 | -15,966,410.88 | | End of Period Cash and Cash Equivalents Balance | 364,120,291.46 | 48,283,675.61 | Audit Information The company's Q1 2023 financial report was unaudited - The company's first-quarter report was unaudited[21]